Buys
Open market- Shares
- Avg price
- Total value
Sukumar Nagendran - President and Head of R&D, Director at Taysha Gene Therapies, Inc.
Issuer-level insider activity
- Role
- President and Head of R&D, Director
- Issuer symbol
- TSHA on Nasdaq
- Entity type
- Individual
- SEC filing history
- Open SEC filing history
Identity
1 identity field
Source evidence
1 source field
Past-year transaction volume for Sukumar Nagendran in Taysha Gene Therapies, Inc.
Sells
Open market- Shares
- -1,143,276
- Avg price
- $4.27
- Total value
- -$4,885,979
Net
Past year- Shares
- -1,143,276
- Share %
- -100%
- Total value
- -$4,885,979
Reported holdings for Sukumar Nagendran in Taysha Gene Therapies, Inc.
Form 4 holding
President and Head of R&D, Director
Taysha Gene Therapies, Inc.
- Security class
- Common Stock
- Shares / value
- 1,136,410
- Estimated value
- $5,068,388
- Report date
- 10 Apr 2026
- Price
- $4.46
- Ownership
- Direct
Form 4 holding
President and Head of R&D, Director
Taysha Gene Therapies, Inc.
- Security class
- Employee Stock Option (right to buy)
- Shares / value
- 455,920
- Estimated value
- Report date
- 10 Apr 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Sukumar Nagendran in Taysha Gene Therapies, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.